LV12271B - Kombinēta vakcīna bērniem ar paaugstinātu katra vakcīnas komponenta imunogēno aktivitāti - Google Patents

Kombinēta vakcīna bērniem ar paaugstinātu katra vakcīnas komponenta imunogēno aktivitāti Download PDF

Info

Publication number
LV12271B
LV12271B LVP-99-29A LV990029A LV12271B LV 12271 B LV12271 B LV 12271B LV 990029 A LV990029 A LV 990029A LV 12271 B LV12271 B LV 12271B
Authority
LV
Latvia
Prior art keywords
vaccine
antigen
diphtheria
tetanus
pertussis
Prior art date
Application number
LVP-99-29A
Other languages
English (en)
Other versions
LV12271A (lv
Inventor
Peter R. Paradiso
Deborah A. Hogerman
Dace Viceps Madore
Jill G. Hackell
Original Assignee
American Cyanamid Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by American Cyanamid Company filed Critical American Cyanamid Company
Publication of LV12271A publication Critical patent/LV12271A/lv
Publication of LV12271B publication Critical patent/LV12271B/lv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Inorganic Compounds Of Heavy Metals (AREA)
  • Peptides Or Proteins (AREA)

Claims (6)

1. Kombinēta vakcīna bērniem, kas satur vienā imunizācijas devā, diftērijas, tetānus un pertussis antigēnu maisījumu un b tipa Haemophilus infiuenzae
5 kapsulu polisaharīda antigēna fragmentu savienojumu un CRM197 proteīnu farmaceitiski pieņemā ūdeni saturošā nesējā, kurā minētā kombinētā vakcīna nodrošina paaugstinātu antivielu veidošanos bērniem pret katru no diftērijas, tetānus, pertussis un b tipa Haemophilus infiuenzae vakcīnas komponentiem.
īo
2. Vakcīna saskaņā ar 1. punktu, kur diftērijas antigēns ir diftērijas toksoīds, tetānus antigēns ir tetānus toksoīds un pertussis antigēns ir deaktivizētas Bordetella pertussis šūnas.
3. Vakcīna saskaņā ar 2. punktu, kur diftērijas toksoīds ir adsorbēts uz alumīnija
15 fosfāta, tetānus toksoīds ir adsorbēts uz alumīnija fosfāta, deaktivizētās
Bordetella pertussis šūnas ir suspendētas šķīdumā, kas satur kālija dihidrogēnfosfātu, nātrija hidrogēnfosfātu un nātrija hlorīdu.
4. Vakcīna saskaņā ar jebkuru no 1. līdz 3. punktam, kas ir pielāgota
20 intramuskulārai ievadīšanai.
5. a) diftērijas antigēnu,
b) tetānus antigēnu,
c) pertussis antigēnu, un
25 d) b tipa Haemophilus infiuenzae kapsulu polisaharīda antigēna fragmentu savienojumu un CRM197 proteīna kombinētā vakcīna, kas paredzēta lietošanai kā vakcīna bērniem.
6. a) diftērijas antigēnu, b) tetānus antigēnu,
LVP-99-29A 1992-10-27 1999-02-22 Kombinēta vakcīna bērniem ar paaugstinātu katra vakcīnas komponenta imunogēno aktivitāti LV12271B (lv)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US96699592A 1992-10-27 1992-10-27

Publications (2)

Publication Number Publication Date
LV12271A LV12271A (lv) 1999-05-20
LV12271B true LV12271B (lv) 1999-07-20

Family

ID=25512167

Family Applications (1)

Application Number Title Priority Date Filing Date
LVP-99-29A LV12271B (lv) 1992-10-27 1999-02-22 Kombinēta vakcīna bērniem ar paaugstinātu katra vakcīnas komponenta imunogēno aktivitāti

Country Status (23)

Country Link
EP (1) EP0594950B1 (lv)
JP (1) JPH07300427A (lv)
KR (1) KR100289224B1 (lv)
AT (1) ATE176157T1 (lv)
AU (1) AU669570B2 (lv)
CA (1) CA2109159A1 (lv)
CZ (1) CZ283587B6 (lv)
DE (2) DE69323264T4 (lv)
DK (1) DK0594950T3 (lv)
ES (1) ES2126616T3 (lv)
FI (1) FI934725A (lv)
GR (1) GR3029884T3 (lv)
HK (1) HK1009931A1 (lv)
HU (1) HU215149B (lv)
IL (1) IL107387A (lv)
LV (1) LV12271B (lv)
NO (1) NO308588B1 (lv)
NZ (1) NZ250029A (lv)
PL (1) PL174130B1 (lv)
RU (1) RU2121365C1 (lv)
SG (1) SG47725A1 (lv)
TW (1) TW256774B (lv)
UA (1) UA27754C2 (lv)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU1864195A (en) * 1994-03-07 1995-09-25 Auckland Uniservices Limited Prevention of diabetes
EP0831901B2 (en) * 1995-06-07 2005-12-07 SMITHKLINE BEECHAM BIOLOGICALS s.a. Vaccine comprising a polysaccharide antigen-carrier protein conjugate and free carrier protein
AP812A (en) 1995-06-23 2000-02-24 Smithkline Biologicals S A A vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate.
US20020054884A1 (en) 1995-06-23 2002-05-09 Smithkline Beecham Biologicals, Sa Vaccine composition comprising a polysaccharide conjugate antigen adsorbed onto aluminium phosphate
TR199802783T2 (xx) * 1996-07-02 1999-03-22 Connaught Laboratories Limited �ok de�erli DTP polyo a��lar.
DK1296715T4 (en) * 2000-06-29 2016-03-07 Smithkline Beecham Biolog Multivalent vaccine composition.
GB0108364D0 (en) * 2001-04-03 2001-05-23 Glaxosmithkline Biolog Sa Vaccine composition
LT1556477T (lt) 2002-11-01 2017-10-25 Glaxosmithkline Biologicals S.A. Džiovinimo būdas
GB0505996D0 (en) * 2005-03-23 2005-04-27 Glaxosmithkline Biolog Sa Fermentation process
DK2283857T3 (da) 2005-06-27 2019-10-28 Glaxosmithkline Biologicals Sa Vaccinesammensætning omfattende konjugerede native N. Meningitidis kapselpolysaccharider

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4902506A (en) * 1983-07-05 1990-02-20 The University Of Rochester Immunogenic conjugates

Also Published As

Publication number Publication date
UA27754C2 (uk) 2000-10-16
FI934725A (fi) 1994-04-28
NO933856D0 (no) 1993-10-26
HU215149B (hu) 2000-03-28
SG47725A1 (en) 1998-04-17
CZ227293A3 (en) 1994-05-18
PL174130B1 (pl) 1998-06-30
GR3029884T3 (en) 1999-07-30
CZ283587B6 (cs) 1998-05-13
KR940008698A (ko) 1994-05-16
CA2109159A1 (en) 1994-04-28
KR100289224B1 (ko) 2001-05-02
JPH07300427A (ja) 1995-11-14
HU9303028D0 (en) 1994-01-28
DE69323264T4 (de) 1999-10-14
TW256774B (lv) 1995-09-11
NO933856L (no) 1994-04-28
AU669570B2 (en) 1996-06-13
HUT67239A (en) 1995-03-28
EP0594950B1 (en) 1999-01-27
NO308588B1 (no) 2000-10-02
AU5029093A (en) 1994-05-12
ES2126616T3 (es) 1999-04-01
ATE176157T1 (de) 1999-02-15
DE69323264D1 (de) 1999-03-11
FI934725A0 (fi) 1993-10-26
DE69323264T2 (de) 1999-06-02
IL107387A0 (en) 1994-01-25
LV12271A (lv) 1999-05-20
NZ250029A (en) 1994-09-27
IL107387A (en) 1997-04-15
EP0594950A1 (en) 1994-05-04
HK1009931A1 (en) 1999-06-11
DK0594950T3 (da) 1999-09-13
RU2121365C1 (ru) 1998-11-10

Similar Documents

Publication Publication Date Title
JP5637848B2 (ja) 髄膜炎ワクチンの製剤化
JP4871770B2 (ja) 組み合わせ髄膜炎ワクチン
US6329512B1 (en) Immunogenic conjugate molecules
TWI286938B (en) Immunogenic compositions comprising polysaccharide conjugate antigens and protein D from haemophilus influenzae, methods of preparing the same and vaccines comprising the same
RU2444374C2 (ru) Получение вакцин, содержащих поверхностный антиген вируса гепатита в и поверхностно-активное вещество
Weinberg et al. Immunologic priming to capsular polysaccharide in infants immunized with Haemophilus influenzae type b polysaccharide—Neisseria meningitidis outer membrane protein conjugate vaccine
RU2420315C2 (ru) Комбинированные вакцины с антигеном коклюша цельных клеток
JP2010529103A5 (lv)
SK283565B6 (sk) Multivalentná imunogénna kompozícia a jej použitie
US9040058B2 (en) Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
EP2661277A2 (en) A combination heptavalent vaccine
Alexander et al. Development of experimental carbohydrate-conjugate vaccines composed of Streptococcus pneumoniae capsular polysaccharides and the universal helper T-lymphocyte epitope (PADRE®)
JP2012506420A (ja) 全細胞百日咳を含む混合ワクチン
EP0594950B1 (en) Combination pediatric vaccine with enhanced immunogenicity of each vaccine component
Redhead et al. Combination of DTP and Haemophilus influenzae type b conjugate vaccines can affect laboratory evaluation of potency and immunogenicity
EP2592137A1 (en) Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
AU2013203663B2 (en) Fermentation media free of animal-derived components for production of diphtheria toxoids suitable for human vaccine use
Schedule et al. Supplementary Table 1: Trials included in Hib conjugate vaccine review, detailed information
Gross 2 Combination Vaccines
PL174077B1 (pl) Szczepionka do ochrony przed zakażeniem lub leczeniem zakażeń Hepatitis B i heterologicznych chorób, zawierająca antygen powierzchniowy Hepatitis B (HBsAg)
GB2498112A (en) Preparation of a diphtheria toxoid by incubating toxin concentrate with an amino acid and formaldehyde